Cervarix

GlaxoSmithKline (NYSE: GSK) is up on Wednesday after missing on first-quarter EPS but beating on revenue. The Brentford, UK-based firm finished with earnings of $0.41 per share, falling far short of the $0.77 Wall Street consensus. Revenue dropped two percent to $9.88 billion, but topped...